Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

Blood Cancer Journal 2026 Open access

Read full text
Authors: Christen M. Dillard, Hans Lee, Nilesh M. Kalariya, Naveen G Subramanian, Oren Pasvolsky, Christopher James Ferreri, Mahmoud Gaballa, Sheeba K. Thomas, Donna M. Weber, Melody Becnel, Gregory Kaufman, Muzaffar H. Qazilbash
+3 more Robert Z. Orlowski, Michelle A. T. Hildebrandt, Krina K. Patel
DOI: 10.1038/s41408-026-01489-9
Cited by: 1
References: 14

Abstract

Novel T-cell directed therapies, including chimeric antigen receptor (CAR)-T cells and bispecific antibodies, have transformed treatment for relapsed/refractory multiple myeloma (RRMM). Although myeloma remains largely incurable, BCMA-directed CAR-T therapy has demonstrated unprecedented efficacy with overall response rates (ORR) of 73–100% and complete response rates of 33–90% [ 1 , 2 ]. However, racial and ethnic minorities, who experience disproportionate myeloma burden with higher incidence and mortality, remain underrepresented in clinical trials [ 3 ], leaving critical gaps in understanding safety and efficacy for these populations [ 4 ].

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Acute Myeloid Leukemia Research Myeloproliferative Neoplasms: Diagnosis and Treatment

Publication details

Journal / source
Blood Cancer Journal
Publisher
Springer Science and Business Media LLC
Volume
16
Issue
1
Publication date
13 April 2026
Language
EN